Anabolic Therapy in Postmenopausal Osteoporosis

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05902078` - Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Phase 4
Completed	`NCT05087030` - Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT01544894` - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis	Phase 4
Completed	`NCT00381251` - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Phase 1
Completed	`NCT00377819` - Study of Transitioning From Alendronate to Denosumab	Phase 3
Completed	`NCT00239629` - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial	Phase 4
Completed	`NCT04026256` - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration	Phase 4
Terminated	`NCT00529373` - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)	Phase 3
Completed	`NCT00092014` - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)	Phase 3
Recruiting	`NCT06079476` - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.	Phase 4
Not yet recruiting	`NCT04719650` - Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid	Phase 4
Recruiting	`NCT02981732` - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome	N/A
Completed	`NCT01709110` - VERtebral Fracture Treatment Comparisons in Osteoporotic Women	Phase 4
Completed	`NCT01348243` - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT00541658` - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis	Phase 3
Completed	`NCT00395395` - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women	Phase 1
Completed	`NCT00247273` - A Study of Monthly Risedronate for Osteoporosis	Phase 3
Active, not recruiting	`NCT03720886` - G56W1 in Women With Postmenopausal Osteoporosis	Phase 1/Phase 2
Completed	`NCT01668589` - Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis	N/A
Completed	`NCT04664959` - A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis	Phase 3

NCT number	NCT05010590
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	March 24, 2022
Completion date	May 1, 2024

Anabolic Therapy in Postmenopausal Osteoporosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms